β common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice

被引:23
作者
Kim, Andrew
Morgan, Kelly
Hasz, Diane E.
Wiesner, Stephen M.
Lauchle, Jennifer O.
Geurts, Jennifer L.
Diers, Miechaleen D.
Le, Doan T.
Kogan, Scott C.
Parada, Luis F.
Shannon, Kevin
Largaespada, David A.
机构
[1] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
[2] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA
[4] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA
[6] Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75230 USA
[7] Univ Texas, SW Med Ctr, Kent Waldrep Fdn, Ctr Basic Neurosci Res, Dallas, TX 75230 USA
关键词
D O I
10.1182/blood-2006-05-025395
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Neurofibromatosis type 1 (NF1) syndrome is caused by germline mutations in the NF1 tumor suppressor, which encodes neurofibromin, a GTPase activating protein for Ras. Children with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML) and lethally irradiated mice given transplants with homozygous Nf1 mutant (Nf1(-/-)) hematopoietic stem cells develop a fatal myeloproliferative disorder (MPD) that models JMML. We investigated the requirement for signaling through the GM-CSF receptor to initiate and sustain this MPD by generating Nf1 mutant hematopoietic cells lacking the common 0 chain (Beta c) of the GM-CSF receptor. Mice reconstituted with Nf1(-/-), beta c(-/-) stem cells did not develop evidence of MPD despite the presence of increased number of immature hematopoietic progenitors in the bone marrow. Interestingly, when the Mx1-Cre transgene was used to inactivate a conditional Nf1 mutant allele in hematopoietic cells, concomitant loss of beta c(-/-) reduced the severity of the MPD, but did not abrogate it. Whereas inhibiting GM-CSF signaling may be of therapeutic benefit in JMML, our data also demonstrate aberrant proliferation of Nf1(-/-) myeloid progenitors that is independent of signaling through the GM-CSF receptor. (Blood. 2007;109: 1687-1691) (c) 2007 by The American Society of Hematology.
引用
收藏
页码:1687 / 1691
页数:5
相关论文
共 24 条
[1]  
Arceci Robert J, 2002, Hematology Am Soc Hematol Educ Program, P297
[2]   Nf1 and Gmcsf interact in myeloid leukemogenesis [J].
Birnbaum, RA ;
O'Marcaigh, A ;
Wardak, Z ;
Zhang, YY ;
Dranoff, G ;
Jacks, T ;
Clapp, DW ;
Shannon, KM .
MOLECULAR CELL, 2000, 5 (01) :189-195
[3]   Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells [J].
Bollag, G ;
Clapp, DW ;
Shih, S ;
Adler, F ;
Zhang, YY ;
Thompson, P ;
Lange, BJ ;
Freedman, MH ;
McCormick, F ;
Jacks, T ;
Shannon, K .
NATURE GENETICS, 1996, 12 (02) :144-148
[4]   TARGETED DISRUPTION OF THE NEUROFIBROMATOSIS TYPE-1 GENE LEADS TO DEVELOPMENTAL ABNORMALITIES IN HEART AND VARIOUS NEURAL CREST-DERIVED TISSUES [J].
BRANNAN, CI ;
PERKINS, AS ;
VOGEL, KS ;
RATNER, N ;
NORDLUND, ML ;
REID, SW ;
BUCHBERG, AM ;
JENKINS, NA ;
PARADA, LF ;
COPELAND, NG .
GENES & DEVELOPMENT, 1994, 8 (09) :1019-1029
[5]   ABNORMAL REGULATION OF MAMMALIAN P21(RAS) CONTRIBUTES TO MALIGNANT-TUMOR GROWTH IN VONRECKLINGHAUSEN (TYPE-1) NEUROFIBROMATOSIS [J].
DECLUE, JE ;
PAPAGEORGE, AG ;
FLETCHER, JA ;
DIEHL, SR ;
RATNER, N ;
VASS, WC ;
LOWY, DR .
CELL, 1992, 69 (02) :265-273
[6]   Juvenile myelomonocytic leukemia: Molecular understanding and prospects for therapy [J].
Emanuel, PD ;
Shannon, KM ;
Castleberry, RP .
MOLECULAR MEDICINE TODAY, 1996, 2 (11) :468-475
[7]  
Hope D G, 1981, Adv Neurol, V29, P33
[8]   Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice [J].
Iversen, PO ;
Lewis, ID ;
Turczynowicz, S ;
Hasle, H ;
Niemeyer, C ;
Schmiegelow, K ;
Bastiras, S ;
Biondi, A ;
Hughes, TP ;
Lopez, AF .
BLOOD, 1997, 90 (12) :4910-4917
[9]   Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21R [J].
Iversen, PO ;
Rodwell, RL ;
Pitcher, L ;
Taylor, KM ;
Lopez, AF .
BLOOD, 1996, 88 (07) :2634-2639
[10]   TUMOR PREDISPOSITION IN MICE HETEROZYGOUS FOR A TARGETED MUTATION IN NF1 [J].
JACKS, T ;
SHIH, TS ;
SCHMITT, EM ;
BRONSON, RT ;
BERNARDS, A ;
WEINBERG, RA .
NATURE GENETICS, 1994, 7 (03) :353-361